Synlogic Q4 2021 net loss $15.1M; cash $136.6M; PKU Phase 3 on track for H2 2022

SYNLOGIC, INC.

Q4 2021 net loss $15.1M ($0.21/share) vs $14.6M ($0.39/share) in Q4 2020; FY 2021 net loss $60.6M ($1.09/share).
Cash, equivalents & marketable securities $136.6M at Dec 31, 2021; projected runway into 2024.
PKU program: Phase 2 SynPheny-1 data expected H1 2022; Phase 3 trial initiation planned H2 2022.
Appointed Michael Jensen as CFO in March 2022; he was formerly CFO of Intrinsic Therapeutics.
HCU candidate SYNB1353 IND submission and Phase 1 healthy volunteer data expected H2 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.